Clinical and translational attributes of immune-related adverse events

被引：0
作者：
Karijn P. M. Suijkerbuijk
Mick J. M. van Eijs
Femke van Wijk
Alexander M. M. Eggermont
机构：
[1] Utrecht University,Department of Medical Oncology, University Medical Center Utrecht
[2] Utrecht University,Center for Translational Immunology, University Medical Center Utrecht
[3] University Medical Center Utrecht and Princess Máxima Center,undefined
[4] Comprehensive Cancer Center Munich of the Technical University of Munich and the Ludwig Maximilian University,undefined
来源：
Nature Cancer | 2024年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many cancers, managing their immune-related adverse events (irAEs) has become an important part of oncological care. This Review covers the clinical presentation of irAEs and crucial aspects of reversibility, fatality and long-term sequelae, with special attention to irAEs in specific patient populations, such as those with autoimmune diseases. In addition, the genetic basis of irAEs, along with cellular and humoral responses to ICI therapy, are discussed. Detrimental effects of empirically used high-dose steroids and second-line immunosuppression, including impaired ICI effectiveness, call for more tailored irAE-treatment strategies. We discuss open therapeutic challenges and propose potential avenues to accelerate personalized management strategies and optimize outcomes.
引用
收藏
页码：557 / 571
页数：14
相关论文
共 234 条
[1]  
Haslam A(2020)Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs JAMA Netw. Open 3 e200423-1729
[2]  
Gill J(2022)Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial Lancet 399 1718-604
[3]  
Prasad V(2023)Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial Nat. Med. 29 593-640
[4]  
Luke JJ(2023)Trends in the approval of cancer therapies by the FDA in the twenty-first century Nat. Rev. Drug Discov. 22 625-778
[5]  
Cascone T(2019)Coverage evaluation of CTCAE for capturing the immune-related adverse events leveraging text mining technologies AMIA Jt Summits Transl. Sci. Proc. 2019 771-271
[6]  
Scott EC(2023)Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology J. Immunother. Cancer 11 e006398-2385
[7]  
Yu Y(2019)Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors JAMA Netw. Open 2 e1911519-2532
[8]  
Naidoo J(2021)Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors Br. J. Dermatol. 185 263-137
[9]  
Hsiehchen D(2017)Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review Ann. Oncol. 28 2377-575
[10]  
Watters MK(2015)Pembrolizumab versus ipilimumab in advanced melanoma N. Engl. J. Med. 372 2521-875
12345678910